Ryan J. Hansen
YOU?
Author Swipe
View article: Enhancing transcription–replication conflict targets ecDNA-positive cancers
Enhancing transcription–replication conflict targets ecDNA-positive cancers Open
Extrachromosomal DNA (ecDNA) presents a major challenge for cancer patients. ecDNA renders tumours treatment resistant by facilitating massive oncogene transcription and rapid genome evolution, contributing to poor patient survival 1–7 . A…
View article: Rampant transcription replication conflict creates therapeutic vulnerability in extrachromosomal DNA containing cancers
Rampant transcription replication conflict creates therapeutic vulnerability in extrachromosomal DNA containing cancers Open
Extrachromosomal DNA (ecDNA) presents a major challenge for precision medicine, contributing to poor survival for patients with oncogene-amplified tumours. EcDNA renders tumours resistant to targeted treatments by facilitating massive tran…
View article: Graphical Abstract: Angew. Chem. Int. Ed. 35/2023
Graphical Abstract: Angew. Chem. Int. Ed. 35/2023 Open
In their Research Article (e202302003), Daniel Huster et al. analyze the dynamics of the human growth hormone secretagogue receptor.The study reveals insights into the energy landscape of the molecule.
View article: Supplementary Figure Legends from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Figure Legends from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Figure Legends - PDF file 100K, Supplementary Figure Legends
View article: Supplementary Table 1 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Table 1 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Table 1 - PDF file 70K, Supplementary Table 1 Top 20 pathways enriched in selumetinib resistant CRC cell lines
View article: Supplementary Figure 2 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary Figure 2 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Highly metastatic osteosarcoma cells activate the mTOR pathway during metastatic progression
View article: Data from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Data from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Purpose: To successfully metastasize, tumor cells must respond appropriately to biological stressors encountered during metastatic progression. We sought to test the hypothesis that enhanced efficiency of mRNA translation during periods of…
View article: Supplementary Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Supplementary Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors Open
Supplementary Figures S1-S4; Supplementary Tables S1-S5.
View article: Supplementary Table 2 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Table 2 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Table 2 - PDF file 62K, Suppl Table 2 IC50s for single agents and combination
View article: Supplementary_Figure_Legends from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary_Figure_Legends from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Legends for Supplementary Tables and Figures
View article: Supplementary Figures 1-6 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Figures 1-6 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Figures 1-6 - PDF file 458K, Power point files of Figures 1-6. For details see legends file
View article: Supplementary Figure Legends from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Figure Legends from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Figure Legends - PDF file 100K, Supplementary Figure Legends
View article: Supplementary_Methods from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary_Methods from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Supplementary Materials and Methods
View article: Supplementary Figure 2 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary Figure 2 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Highly metastatic osteosarcoma cells activate the mTOR pathway during metastatic progression
View article: Supplementary_Methods from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary_Methods from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Supplementary Materials and Methods
View article: Supplementary Figures 1-6 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Figures 1-6 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Figures 1-6 - PDF file 458K, Power point files of Figures 1-6. For details see legends file
View article: Supplementary Table 2 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Table 2 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Table 2 - PDF file 62K, Suppl Table 2 IC50s for single agents and combination
View article: Supplementary Figure 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary Figure 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
5' UTR structures of BONCAT identified proteins
View article: Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors Open
Purpose: ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD, pharmacokinetic, and pharmacodynamic profiles and preliminary antitumor activity…
View article: Supplementary Table 1 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Table 1 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Table 1 - PDF file 70K, Supplementary Table 1 Top 20 pathways enriched in selumetinib resistant CRC cell lines
View article: Supplementary Table 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary Table 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Summary of BONCAT proteomic analysis of mRNA translation during metastasis
View article: Supplementary Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Supplementary Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors Open
Supplementary Figures S1-S4; Supplementary Tables S1-S5.
View article: Data from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Data from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Purpose: The mitogen-activated protein kinase (MAPK) pathway is a crucial regulator of cell proliferation, survival, and resistance to apoptosis. MEK inhibitors are being explored as a treatment option for patients with KRAS-mutant colorec…
View article: Supplementary_Figure_Legends from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary_Figure_Legends from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Legends for Supplementary Tables and Figures
View article: Data from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Data from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
Purpose: To successfully metastasize, tumor cells must respond appropriately to biological stressors encountered during metastatic progression. We sought to test the hypothesis that enhanced efficiency of mRNA translation during periods of…
View article: Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors Open
Purpose: ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD, pharmacokinetic, and pharmacodynamic profiles and preliminary antitumor activity…
View article: Supplementary Methods from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Supplementary Methods from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Supplementary Methods - PDF file 124K, Supplementary Methods
View article: Supplementary Figure 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>
Supplementary Figure 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> Open
5' UTR structures of BONCAT identified proteins
View article: Data from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Data from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer Open
Purpose: The mitogen-activated protein kinase (MAPK) pathway is a crucial regulator of cell proliferation, survival, and resistance to apoptosis. MEK inhibitors are being explored as a treatment option for patients with KRAS-mutant colorec…